医学
内科学
三阴性乳腺癌
乳腺癌
肿瘤科
新辅助治疗
三重阴性
完全响应
癌症
化疗
作者
Laura M. Spring,Sara M. Tolaney,Geoffrey Fell,Veerle Bossuyt,Rachel O. Abelman,Bing Wu,Shyamala Maheswaran,Lorenzo Trippa,Amy Comander,Therese M. Mulvey,Sarah A. McLaughlin,Paula D. Ryan,Louise Ryan,Edward Abraham,Aron S. Rosenstock,Ana C. Garrido-Castro,Filipa Lynce,Beverly Moy,Steven J. Isakoff,Nadine Tung,Elizabeth A. Mittendorf,Leif W. Ellisen,Aditya Bardia
标识
DOI：10.1016/j.annonc.2023.11.018
摘要
Sacituzumab govitecan (SG), a novel antibody-drug conjugate (ADC) targeting TROP2, is approved for pre-treated metastatic triple-negative breast cancer (mTNBC). We conducted an investigator-initiated clinical trial evaluating neoadjuvant (NA) SG (NCT04230109), and report primary results.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cctv18
ppg123
一一
彭于彦祖
monere
maox1aoxin
zho
港岛妹妹
嗯哼
小鱼爱吃肉
背带裤打篮球
tuanheqi
坚强的广山
pluto
8R60d8
36456657
besatified
不配.
带头大哥
双黄
皖公网安备34019202002308
